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Adjuvant bisphosphonate treatment in early breast cancer: 
meta-analyses of individual patient data from randomised 
trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*
Summary
Background Bisphosphonates have profound eﬀ ects on bone physiology, and could modify the process of metastasis. 
We undertook collaborative meta-analyses to clarify the risks and beneﬁ ts of adjuvant bisphosphonate treatment in 
breast cancer.
Methods We sought individual patient data from all unconfounded trials in early breast cancer that randomised 
between bisphosphonate and control. Primary outcomes were recurrence, distant recurrence, and breast cancer 
mortality. Primary subgroup investigations were site of ﬁ rst distant recurrence (bone or other), menopausal status 
(postmenopausal [combining natural and artiﬁ cial] or not), and bisphosphonate class (aminobisphosphonate 
[eg, zoledronic acid, ibandronate, pamidronate] or other [ie, clodronate]). Intention-to-treat log-rank methods yielded 
bisphosphonate versus control ﬁ rst-event rate ratios (RRs).
Findings We received data on 18 766 women (18 206 [97%] in trials of 2–5 years of bisphosphonate) with median 
follow-up 5·6 woman-years, 3453 ﬁ rst recurrences, and 2106 subsequent deaths. Overall, the reductions in recurrence 
(RR 0·94, 95% CI 0·87–1·01; 2p=0·08), distant recurrence (0·92, 0·85–0·99; 2p=0·03), and breast cancer mortality 
(0·91, 0·83–0·99; 2p=0·04) were of only borderline signiﬁ cance, but the reduction in bone recurrence was more 
deﬁ nite (0·83, 0·73–0·94; 2p=0·004). Among premenopausal women, treatment had no apparent eﬀ ect on any 
outcome, but among 11 767 postmenopausal women it produced highly signiﬁ cant reductions in recurrence (RR 0·86, 
95% CI 0·78–0·94; 2p=0·002), distant recurrence (0·82, 0·74–0·92; 2p=0·0003), bone recurrence (0·72, 0·60–0·86; 
2p=0·0002), and breast cancer mortality (0·82, 0·73–0·93; 2p=0·002). Even for bone recurrence, however, the 
heterogeneity of beneﬁ t was barely signiﬁ cant by menopausal status (2p=0·06 for trend with menopausal status) or 
age (2p=0·03), and it was non-signiﬁ cant by bisphosphonate class, treatment schedule, oestrogen receptor status, 
nodes, tumour grade, or concomitant chemotherapy. No diﬀ erences were seen in non-breast cancer mortality. Bone 
fractures were reduced (RR 0·85, 95% CI 0·75–0·97; 2p=0·02).
Interpretation Adjuvant bisphosphonates reduce the rate of breast cancer recurrence in the bone and improve breast 
cancer survival, but there is deﬁ nite beneﬁ t only in women who were postmenopausal when treatment began.
Funding Cancer Research UK, Medical Research Council.
Copyright © Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Open Access article distributed under the 
terms of CC BY.
Introduction
Circulating tumour cells can be attracted to surfaces within 
the bone where they can displace haemopoietic stem cells 
and bind to the osteoblastic niche.1 These disseminated 
malignant cells can remain quiescent for years. Then, for 
reasons that are not well understood, they can exit this 
dormant state, start to proliferate, and establish macro-
metastases in the bone or elsewhere.2,3 Bisphosphonates 
have profound eﬀ ects on osteoclasts, and aﬀ ect T-cell 
function, so could also be eﬀ ective as adjuvant treatments, 
particularly in preventing or delaying bone recurrence.4–6 
For this reason, and because bisphosphonates can be added 
to the aromatase inhibitor treatment of post menopausal 
breast cancer to restrict adverse skeletal eﬀ ects of oestrogen 
deprivation, reliable evidence is needed about the eﬀ ects of 
bisphosphonates on breast cancer outcomes.
Improvements in bone-metastasis-free survival, disease-
free survival, and overall survival in women with early 
breast cancer have been reported in some adjuvant trials of 
oral clodronate7,8 or of intravenous zoledronic acid.9,10 
However, in other trials of adjuvant bisphos phonates no 
signiﬁ cant beneﬁ ts were seen in analyses that included all 
randomised patients, although both planned and 
exploratory subset analyses suggested beneﬁ ts either in 
postmenopausal women11 or in older women.12,13 This led to 
the hypothesis11–13 that treatment is of beneﬁ t only in 
patients with low concentrations of reproductive hormones 
(ie, those who are postmenopausal or undergoing ovarian 
suppression therapy).14–16
To help clarify whether adjuvant bisphosphonates reduce 
the risk of bone and other metastases, and whether meno-
pausal status aﬀ ects eﬃ  cacy, we undertook collab orative 
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meta-analyses of all unconfounded randomised trials that 
compared breast cancer outcomes in those allocated 
adjuvant bisphosphonate versus those who were not.
Methods
Identiﬁ cation of studies and collection of data
The methods of identifying trials, seeking collaboration, 
data collection, collation, checking, and pres entation are as 
in previous Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG) reports.17–19 Trials were eligible if they 
began before 2008 and randomly assigned women be-
tween a bisphosphonate of any type, dose, and schedule 
versus a control group (open label or placebo) with no 
bisphosphonate, all other treatments being similar in both 
groups. Information was sought during 2012–14 for each 
individual patient on date of randomisation, allocated treat-
ment, age, menopausal status, tumour diameter, grade, 
spread to locoregional lymph nodes, HER2 and oestrogen 
and progesterone receptor (ER/PR) status, dates and sites 
of any breast cancer recurrence, other second pri mary 
cancer, bone fracture, and the date and cause of death.
The main deﬁ nitions and analysis methods are those 
used in previous EBCTCG reports,17–19 but with some 
amendments that reﬂ ect the potential eﬀ ect of 
bisphosphonates on bone metastases (appendix).
Outcomes
The pre-deﬁ ned coprimary endpoints were any recurrence 
of breast cancer (distant, locoregional, or new primary in 
the contralateral breast); distant recurrence, ignoring any 
previous locoregional or contralateral recurrence; and 
breast cancer mortality (estimated by log-rank subtraction, 
as in previous EBCTCG reports18,19).
Secondary outcomes were all-cause mortality; death 
without recurrence; bone recurrence as the ﬁ rst distant 
recurrence (with or without concurrent other recurrence); 
other ﬁ rst (extraskeletal) distant recurrence (with all 
analyses of distant recurrence ignoring any previous 
locoregional or contralateral recurrence); locoregional 
recurrence as ﬁ rst event (ipsilateral breast, chest wall, or 
locoregional lymph nodes); contralateral new primary 
breast cancer as ﬁ rst event; and any bone fractures.
Statistical analyses
Time-to-event analyses were stratiﬁ ed by age, ER status, 
nodal status, and trial. Within each stratum, they 
compared all those allocated bisphosphonate versus 
all those allocated control, regardless of treatment 
compliance (yielding intention-to-treat analyses). 
Log-rank statistics were used to assess the eﬀ ects 
(bisphosphonate vs control) on various outcomes, and, 
for each, to estimate ﬁ rst-event rate ratios (RRs) and their 
CIs. We did statistical analyses using EBCTCG in-house 
Fortran programs.
Pre-speciﬁ ed primary subgroup investigations were of 
site of ﬁ rst distant recurrence (bone, other), menopausal 
status (premenopausal, perimenopausal, post menopausal 
[natural or induced, either potentially reversibly, using 
luteinising hormone-releasing hormone analogues, or 
permanently by oophorectomy] or, if menopausal status 
was unavailable, years of age, grouped as <45, 45–54, 
≥55 years), and class of bisphosphonate (amino bisphos-
phonate [zoledronic acid, ibandronate, pamidronate, 
risedronate, alendronate], other [clodronate]). Exploratory 
investigations were undertaken of potential interactions 
between treatment eﬃ  cacy and ER status, nodal status, 
histological grade, use or not of adjuvant chemotherapy, 
and follow-up period. If appropriate, tests comparing 
eﬀ ects in diﬀ erent subgroups were for trend rather than 
heterogeneity.
We pre-speciﬁ ed that comparisons of treatment eﬃ  cacy 
within subgroups would exclude local and contralateral 
recurrence if the prior hypothesis that bisphosphonates 
would reduce distant but not local or contralateral 
recurrence was established from analyses of the overall 
results in all randomised patients. As bone recurrence 
was the only type of recurrence signiﬁ cantly reduced by 
bisphosphonates we used this instead as the primary 
endpoint for subgroup comparisons, but the appendix 
includes subgroup analyses for any distant recurrence. 
Because the ABCSG-129 and AZURE11,14 trials had helped 
generate the hypothesis of the relevance of menopausal 
status to the eﬀ ects of treatment, we provide sensitivity 
analyses of this hypothesis that treated these trials as 
hypothesis-generating, with the remaining trials 
hypothesis-testing. The policy on data sharing from this 
study is available online.
See Online for appendix
Studies identiﬁ ed Studies with data received
Trials (n) Patients (n) Trials (n) Patients (n) %* Years†
Up to 1 year of treatment
<1 year clodronate 2 120 1 72 60% 0·5
<1 year aminobisphosphonate 2 208 1 40 19% 0·1
1 year aminobisphosphonate 7 1088 3 448 41% 1·0
Total for ≤1 year of treatment 11 1416 5 560 40% 0·9
2–5 years of treatment
2 years clodronate 4 3978 3 3912 98% 2·0
3–5 years clodronate 1 1069 1 1069 100% 3·0
2 years aminobisphosphonate 10 3654 8 3514 96% 2·0
3–5 years aminobisphosphonate 12 11 910‡ 9 9711 82%‡ 4·5
Total for 2–5 years of treatment 27 20 611‡ 21 18 206 88%‡ 3·5
Any clodronate regimen 7 5167 5 5053 98% 2·6
Any aminobisphosphonate§ 31 16 860‡ 21 13 713 81%‡ 3·8
Total, all regimens 38 22 027‡ 26 18 766 85%‡ 3·4
*Number of patients with data received as a percentage of all randomised patients in identiﬁ ed studies. †Mean 
scheduled treatment duration (weighted in proportion to numbers of patients with data received). ‡Includes two trials 
(2116 patients) still in progress; excluding these, the total with data received is 94%. §The aminobisphosphonates in 
these trials were zoledronic acid (9290 patients with data received, 1582 recurrences [46% of all recurrences]), 
ibandronate (3072 patients, 380 recurrences [11%]), pamidronate (953 patients, 473 recurrences [14%]), 
risedronate (398 patients, 13 recurrences [0·4%]), and alendronate (no trials with data received); the only 
non-aminobisphosphonate in these trials was clodronate (5053 patients, 1005 [29%] recurrences).
Table: Numbers of unconfounded randomised trials of an adjuvant bisphosphonate identiﬁ ed, and 
numbers with data received, by duration and type of bisphosphonate treatment
For the CTSU policy on data 
sharing see http://www.ctsu.ox.
ac.uk/research/data-access-
policies/data-access-and-
sharing-policy/view
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The writing committee had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Individual patient datasets were provided for 26 trials 
with 18 766 participants, 97% of all 19 291 women in the 
32 completed trials that recorded recurrence data (table, 
appendix). In four other trials (620 women) recurrence was 
not recorded, and from the two ongoing trials (2116 women) 
outcome data cannot yet be provided. Mean scheduled 
treatment duration was 3·4 years; 18 206 (97%) of 
18 766 participants were in trials of 2–5 years of treatment. 
Median follow-up was 5·6 woman-years (IQR 3·7–8·0). 
3453 women had a recurrence, after which 2106 died.
Recurrence rates were slightly lower with than without 
bisphosphonates, but this was not signiﬁ cant in analyses 
that included all 18 766 women (RR 0·94, 95% CI 
0·87–1·01; 2p=0·08; ﬁ gure 1). However, there was a 
borderline signiﬁ cant reduction in the risk of distant 
recurrence, ignoring any previous local or contralateral 
Figure 1: Recurrence by site and breast cancer mortality in 24 trials of bisphosphonate versus no bisphosphonate (control)
Kaplan-Meier graphs showing eﬀ ects of treatment allocation on 10-year outcomes in all 18 766 patients. (A) Any recurrence. (B) Distant recurrence. (C) Bone recurrence. 
(D) Breast cancer mortality. O–E=observed minus expected. V=variance of O–E. RR=rate ratio (exp[{O–E}/V]). Error bars are SE. 
Recurrence rate/year (%), events/woman-years and log-rank statistics
Allocation
Bisphosphonate
Control
Rate ratio (95% CI) 
from (O–E)/V
18 766 women
RR 0·94 (95% CI 0·87–1·01)
Log-rank 2p=0·08
10-year gain 1·1% (95% CI –0·7 to 2·9)
Control 25·9%
Bisphosphonate 24·9%
 Years 0–4
 3·63 (1415/38 979)
 3·85 (1384/35 984)
 0·93 (0·85–1·01)
 –41·9/593·7
 Years 5–9
 2·34 (308/13 171)
 2·36 (314/13 322)
 0·98 (0·81–1·14)
 –3·1/139·4
 Years ≥10
 0·87 (15/1724)
 0·95 (17/1790)
 0·72 (CI 0·01–1·43)
 –1·8/5·5
17·4%
16·3%
0
10
20
30
40
50
Re
cu
rre
nc
e 
(%
)
A
Distant recurrence rate/year (%), events/woman-years and log-rank statistics
Allocation
Bisphosphonate
Control
Rate ratio (95% CI) 
from (O–E)/V
18 766 women
RR 0·92 (95% CI 0·85–0·99)
Log-rank 2p=0·03
10-year gain 1·4% (95% CI –0·3 to 3·1)
Control 21·8%
Bisphosphonate 20·4%
 Years 0–4
 2·97 (1173/39 559)
 3·20 (1170/36 571)
 0·91 (0·83–0·99)
 –47·5/499·9
 Years 5–9
 1·84 (253/13 746)
 1·82 (253/13 931)
 0·99 (0·81–1·18)
 –0·7/114·3
 Years ≥10
 0·67 (13/1932)
 1·08 (21/1941)
 0·47 (0·21–1·03)
 –4·5/5·9
14·8%
13·5%
0
10
20
30
40
50
Di
st
an
t r
ec
ur
re
nc
e 
(%
)
B
Bone recurrence rate/year (%), events/woman-years and log-rank statistics
Allocation
Bisphosphonate
Control
Rate ratio (95% CI) 
from (O–E)/V
18 766 women
RR 0·83 (95% CI 0·73–0·94)
Log-rank 2p=0·004
10-year gain 1·1% (95% CI –0·1 to 2·3)
Control 9·0%
Bisphosphonate 7·8%
0 5 10
 Years 0–4
 0·99 (391/39 559)
 1·21 (441/36 571)
 0·79 (0·66–0·92)
 –45·0/189·5
   Years 5–9
 0·76 (104/13 746)
 0·71 (99/13 031)
 1·02 (0·73–1·31)
 0·8/46·8
 Years ≥10
 0·10 (2/1932)
 0·10 (2/1941)
 0·61 (0·08–2·25)
 –0·4/0·9
Years
5·9%
4·7%
0
10
20
30
40
50
Bo
ne
 re
cu
rre
nc
e 
(%
)
C
Death rates (%/year: total rate minus rate in women without recurrences) and log-rank statisti
Allocation
Bisphosphonate
Control
Rate ratio (95% CI)
from (O–E)/V
18 766 women
RR 0·91 (95% CI 0·83–0·99)
Log-rank 2p=0·04
10-year gain 1·7% (95% CI 0·0 to 3·5)
Control 18·4%
Bisphosphonate 16·6%
0 5 10
 Years 0–4
 1·83 (1·70–1·97)
 1·98 (1·84–2·12)
 0·91 (0·81–1·01)
 –30·5/321·7
 Years 5–9
 1·81 (1·59–2·03)
 1·97 (1·75–2·20)
 0·92 (0·75–1·10)
 –9·5/121·0
 Years ≥10
 1·21 (0·72–1·69)
 1·69 (1·12–2·25)
 0·66 (0·18–1·15)
 –4·5/10·9
Years
9·7%
8·9%
0
10
20
30
40
50
Br
ea
st
 ca
nc
er
 m
or
ta
lit
y 
(%
)
D
Articles
1356 www.thelancet.com   Vol 386   October 3, 2015
Figure 2: Multiple subgroup analyses of eﬀ ects on bone recurrence in trials of bisphosphonate versus no bisphosphonate (control)
Results are plotted as black squares with horizontal lines that denote 99% rather than 95% CIs to allow for multiple hypothesis testing. Total is plotted as a white 
diamond that denotes 95% CI. ER=oestrogen receptor. O–E=observed minus expected.
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breast recurrence (10-year risk 20·4% bisphosphonate vs 
21·8% control; RR 0·92, 95% CI 0·85–0·99; 2p=0·03; 
ﬁ gure 1), whereas there was no signiﬁ cant eﬀ ect on the 
incidence of local recurrence as ﬁ rst event (RR 1·10, 
0·94–1·28; 2p=0·25; appendix) or of contralateral breast 
cancer as ﬁ rst event (RR 0·96, 0·74–1·25; 2p=0·79). The 
greater eﬃ  cacy of bis phosphonates in preventing distant 
recurrence than in preventing other (local or contralateral) 
breast cancer recurrence was signiﬁ cant (test for 
interaction 2p=0·01).
The eﬀ ect on distant recurrence was mainly because of a 
reduction in bone recurrence (10-year risk 7·8% vs 9·0%; 
RR 0·83, 95% CI 0·73–0·94; 2p=0·004; ﬁ gure 1). There 
was signiﬁ cantly (p=0·04) greater eﬀ ect on bone recurrence 
than on other ﬁ rst distant recurrence (RR 0·98, 95% CI 
0·89–1·08; 2p=0·69; appendix), although this apparent 
lack of eﬃ  cacy could be partly because delay of bone 
recurrence with bisphosphonate in a woman who would 
otherwise have had both bone and other distant recurrence 
allowed the other recurrence to be the ﬁ rst event.
Breast cancer mortality was borderline signiﬁ cantly 
lower in patients allocated bisphosphonate than control 
(10-year risk 16·6% vs 18·4%; RR 0·91, 95% CI 0·83–0·99; 
2p=0·04; ﬁ gure 1), and all-cause mortality was similarly 
reduced (10-year risk 20·8% vs 22·3%; RR 0·92, 
0·85–1·00; 2p=0·06; appendix). Of 2607 deaths from any 
cause, 501 (19%) were in recurrence-free women; this 
non-breast cancer mortality appeared to be unaﬀ ected by 
the treatment allocation (RR 0·99, 95% CI 0·82–1·19; 
2p=0·91).
We did many subgroup analyses to investigate the eﬀ ects 
of bisphosphonates on any recurrence, distant recurrence, 
bone recurrence, and breast cancer mortality (appendix). 
In the overall analyses, among all 18 766 women, the 
clearest evidence of eﬀ ect of bis phosphonates was, as 
anticipated, on bone recurrence, so the most informative 
subgroup analyses should relate to this endpoint (ﬁ gure 2). 
The eﬃ  cacy of bisphosphonates in reducing bone 
recurrence appeared to be greater in older women 
(2p=0·03 for trend with age in treatment eﬀ ect) or, 
similarly, in postmenopausal women (2p=0·06 for trend 
with menopausal status). As menopausal status and age 
are closely correlated, we cannot determine reliably which 
is more relevant (appendix). Among the 4616 women 
younger than 45 years, bone recurrence appeared to be 
unaﬀ ected by the treatment allocation (RR 1·00, 95% CI 
0·79–1·26; 2p=0·97), but among the 7388 women 55 years 
or older there was a highly signiﬁ cant treatment eﬀ ect (RR 
0·72, 0·59–0·88; 2p=0·002). Sensitivity analyses of the 
possible relevance of age and menopausal status that 
omitted the hypothesis-generating ABCSG-129 and 
AZURE11,14 studies still showed signiﬁ cant (2p=0·004) 
beneﬁ t only in post menopausal women (appendix). As 
was the case for bone recurrence, the reductions in any 
distant recurrence with bisphosphonate were also 
signiﬁ cantly greater in older women (2p=0·003 for trend 
with age) and post menopausal women (2p=0·01).
None of the other subgroup analyses of bone recurrence 
in ﬁ gure 2 revealed any signiﬁ cant evidence of 
heterogeneity of beneﬁ t by tumour type (or for other 
breast cancer outcomes; appendix). Although the beneﬁ t 
appeared somewhat larger in ER-negative than ER-positive 
disease and in node-positive than node-negative tumours, 
this apparent heterogeneity of treatment eﬀ ect did not 
approach signiﬁ cance and could be a chance ﬁ nding.
Likewise, there was no signiﬁ cant heterogeneity 
between the apparent eﬀ ects on bone recurrence of 
the diﬀ erent bisphosphonate regimens tested in these 
trials. For this outcome, the beneﬁ ts of the non-
amino bisphosphonate (clodronate, n=5053) and of the 
two most widely tested aminobisphosphonates (zoledronic 
acid, n=9290, and ibandronate, n=3072) appeared similar, 
but there was no apparent beneﬁ t in the smaller oral 
pamidronate group (n=953).
For bone recurrence, the beneﬁ ts appeared to be similar 
in trials of low-intensity anti-osteoporosis schedules (eg, 
6-monthly intravenous zoledronic acid) and in trials of 
more intensive schedules such as those approved for use 
in metastatic bone disease (eg, monthly zoledronic acid, 
daily oral ibandronate, or daily oral clodronate). Likewise, 
the average eﬀ ect appeared similar in trials that tested 
diﬀ erent durations of treatment (trials of 2 years 
bisphosphonate vs none: RR 0·76, 95% CI 0·60–0·97; 
2p=0·026; trials of 3–5 years bisphosphonate vs none: 
RR 0·85, 0·73–0·99; 2p=0·037; ﬁ gure 2), and in the 
presence or absence of chemotherapy. There were 
signiﬁ cant reductions in bone recurrence during years 
0–1 and years 2–4 after randomisation but there appeared 
to be no further reduction thereafter. Again, though, this 
decrease in treatment eﬀ ect over time was not signiﬁ cant 
(trend 2p=0·11), perhaps because there is thus far only 
limited follow-up after the ﬁ rst 5 years.
The 10-year disease outcomes for premenopausal and 
postmenopausal women separately are summarised in 
ﬁ gure 3 and the appendix. In premenopausal women, 
treatment appeared to have little eﬀ ect on bone metastases 
or breast cancer mortality, whereas in postmenopausal 
women it produced highly signiﬁ cant reductions in 
recurrence (RR 0·86, 95% CI 0·78–0·94; 2p=0·002; 
appendix), distant recurrence (RR 0·82, 0·74–0·92; 
2p=0·0003; appendix), bone recurrence (RR 0·72, 
0·60–0·86; 2p=0·0002), and breast cancer mortality 
(RR 0·82, 0·73–0·93; 2p=0·002). In both menopausal 
subgroups, rates of ﬁ rst distant recurrence at sites other 
than bone appeared to be unaﬀ ected by treatment. In the 
postmenopausal subgroup, for bone recurrence the 
absolute gain from treatment was 2·2% (95% CI 0·6–3·8) 
(10-year risks 6·6% vs 8·8%; RR 0·72, 95% CI 0·60–0·86; 
2p=0·0002), whereas for breast cancer mortality the 
absolute gain was 3·3% (95% CI 0·8–5·7) (10-year risks 
14·7% vs 18·0%; RR 0·82, 0·73–0·93; 2p=0·002).
To enhance statistical power, the multiple subgroup 
analyses of bone recurrence (ﬁ gure 2) and the 
corresponding analyses of other outcomes (appendix) can 
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Figure 3: Main outcomes in 
premenopausal (excluding 
perimenopausal) and in 
postmenopausal women in 
trials of bisphosphonate 
versus no bisphosphonate 
(control)
Kaplan-Meier graphs showing 
the eﬀ ects of treatment 
allocation on 10-year breast 
cancer outcomes. 
(A) Premenopausal and 
(B) postmenopausal bone 
recurrence. (C) Premenopausal 
and (D) postmenopausal 
distant recurrence outside the 
bone. (E) Premenopausal and 
(F) postmenopausal breast 
cancer mortality. 
O-E=observed minus 
expected. V=variance of O–E. 
RR=rate ratio (exp[{O–E}/V]). 
Error bars are SE .
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all be restricted to postmenopausal women (appendix). In 
postmenopausal women, there was signiﬁ cant (p=0·01) 
heterogeneity between agents in the reductions in bone 
recurrence, explained by the apparent lack of beneﬁ t from 
pamidronate. The clodronate results did appear somewhat 
more promising than the aminobisphosphonate results 
but this diﬀ erence was not signiﬁ cant for distant 
recurrence or for bone recurrence, and was of only 
borderline signiﬁ cance for breast cancer mortality, even 
though the reduction in postmenopausal breast cancer 
mortality was signiﬁ cant with clodronate but not with the 
aggregate of all aminobisphosphonate regimens.
Information on fractures was available from only 
13 341 (71%) of 18 766 women. Among them, 422 (6·3%) of 
6649 bisphosphonate-allocated patients had a fracture 
reported, as against 487 (7·3%) of 6692 control patients 
(RR 0·85, 95% CI 0·75–0·97; 2p=0·02; appendix), and the 
5-year fracture risk was reduced from 6·3% to 5·1%, with 
little eﬀ ect in years 0–1 and most of the gain in years 2–4. 
After year 5 there appeared to be little further gain, but in 
both groups the absolute rates after year 5 were lower than 
in years 0–4, perhaps reﬂ ecting incomplete ascertainment.
Discussion
Taking all women together, regardless of menopausal 
status, this collaborative meta-analysis of individual 
patient data from 18 766 women randomised in trials of 
adjuvant bisphosphonates found a highly signiﬁ cant 
reduction only in bone recurrence, and not in other 
breast cancer outcomes. Subgroup analyses suggested 
beneﬁ t just in postmenopausal women, among whom 
there were highly signiﬁ cant reductions not only in bone 
recurrence but also in any distant recurrence (bone or 
other), breast cancer mortality, and overall mortality.
Neither in the overall results nor in the results just 
among postmenopausal women, however, was there any 
signiﬁ cant eﬀ ect on distant recurrence at extra-osseous 
sites, on locoregional recurrence, or on the incidence of 
contralateral breast cancer. The lack of eﬀ ect on new 
contralateral breast cancers is consistent with ﬁ ndings 
of the large FIT and HORIZON-PFT fracture prevention 
trials,20 but contrasts with reports from epidemiological 
studies that breast cancer incidence is reduced in 
postmenopausal women taking bisphosphonates for 
osteoporosis.21,22 Thus, the randomised evidence provides 
no support for the use of bisphosphonates as a breast 
cancer chemoprevention strategy.
Though the statistical signiﬁ cance of the apparent 
interaction between menopausal status and treatment 
eﬃ  cacy is not extreme, greater beneﬁ t for postmenopausal 
women had been hypothesised to explain the apparent 
discordance between the ABCSG-129 and AZURE11,14 trial 
results. Sensitivity analyses that excluded these two 
hypothesis-generating datasets only marginally weakened 
the evidence of an interaction with menopausal status, 
and the beneﬁ t was still signiﬁ cant in the remaining 
postmenopausal women.
Moreover, there is some preclinical evidence that 
reproductive hormones can inhibit bisphosphonate 
eﬃ  cacy against cancer cells in the bone. The eﬀ ects of 
zoledronic acid (100 μg/kg weekly) on the growth of 
disseminated MDA-231 breast cancer cells in bone were 
compared in ovariectomised mice (modelling the 
postmenopausal setting) and in sham-operated mice 
(modelling the premenopausal setting). Zoledronic acid 
decreased the number of detectable tumours in bone only 
in the ovariectomised animals.23 Likewise, in a prostate 
cancer mouse model the ability of disseminated tumour 
cells in the bone to form detectable tumours was inhibited 
by zoledronic acid only in castrated mice, not in sham-
operated mice.24
The eﬀ ects on bone recurrence emphasise the potential 
importance of host microenvironment factors to 
metastasis. Further studies are needed to clarify why 
menopausal status should importantly aﬀ ect the response 
to bisphosphonates. The complex interactions between 
reproductive hormones, tumour biology, bone cell 
function, and bone marrow stem cells could well change 
as patients progress from the premenopausal setting, 
where oestradiol and inhibin are of major importance in 
bones, to the postmenopausal setting, where activin and 
other members of the TGF-β superfamily become the 
main regulators of bone cell metabolism.25 A clearer 
understanding of some of the other mechanisms involved 
in the development of bone metastasis is now emerging, 
although how these relate to menopausal status and 
reproductive hormones remains unknown.26 
Other than the apparent eﬀ ect of menopausal status or, 
similarly, age on treatment eﬃ  cacy, the proportional 
reductions in bone recurrence and breast cancer mortality 
with treatment did not depend signiﬁ cantly on other 
patient or clinico pathological primary tumour character-
istics, including ER status, axillary lymph node involve-
ment, and tumour grade. Similar reductions were seen in 
the presence and absence of chemotherapy, suggesting 
that the beneﬁ ts of bisphosphonates are approximately 
additive to those of chemotherapy, and vice versa.
As subgroup analyses can yield erratic results, it is 
diﬃ  cult to determine from them whether diﬀ erent 
bisphosphonate regimens have diﬀ erent eﬀ ects. The 
endpoint that should yield the most reliable subgroup 
analyses is bone recurrence. Both for all women and for 
postmenopausal women, subgroup analyses of bone 
recurrence suggested similar eﬀ ects of oral clodronate 
and of the aggregate of all aminobisphosphonate 
regimens (mainly intravenous zoledronic acid). Likewise, 
they suggested no signiﬁ cant heterogeneity in eﬃ  cacy 
between the diﬀ erent aminobisphosphonates, though no 
beneﬁ t was seen with oral pamidronate (which could be 
real, as oral pamidronate is poorly absorbed, has little 
eﬀ ect on bone resorption biomarkers or the underlying 
metastatic bone disease, and failed to show eﬃ  cacy in 
myeloma27,28). Numbers were insuﬃ  cient to assess the 
eﬃ  cacy of the standard treatments for osteoporosis, oral 
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risedronate or alendronate, as therapy for early breast 
cancer. Subgroup analyses based instead on breast cancer 
mortality suggested a greater eﬀ ect with clodronate than 
with aminobisphosphonates. However, as the two drugs 
appeared to have similar eﬀ ects on bone recurrence, their 
apparently diﬀ erent eﬀ ects on breast cancer mortality 
could be a chance ﬁ nding.
Much more reliable comparisons of diﬀ erent bis-
phosphonate regimens will emerge from ongoing trials 
that compare them directly. The SWOG0307 trial 
(NCT00127205) comparing clodronate versus zoledronic 
acid versus ibandronate in 5400 patients has completed 
recruit ment and addresses the choice of agent; the 
SUCCESS trial (NCT02181101) comparing 5 years versus 
2 years of zoledronic acid in 3800 patients has also 
completed recruitment and addresses duration. Similarly, 
results from two ongoing trials (HOBOE-premenopausal 
[NCT00412022] and TEAM-IIb [ISRCTN17633610]), plus 
longer follow-up of the trials included in this meta-
analysis, will eventually provide better evidence on any 
eﬀ ect of bisphosphonates in premenopausal women, and 
will provide more stable estimates of the 10-year outcomes 
in postmenopausal women.
Consistent with the known eﬀ ects on bone mineral 
density and quality, the use of adjuvant bisphosphonates 
was associated with a small reduction in fracture incidence. 
Although not highly signiﬁ cant, it can be accepted as real 
because of evidence of fracture reduction in other types 
of patient. There was no apparent eﬀ ect of adjuvant 
bisphosphonates on non-breast cancer mortality. Major 
adverse events with bisphosphonates are uncommon, but 
can include impaired renal function and osteonecrosis of 
the jaw. From the data provided, we were unable to assess 
the incidence of osteonecrosis of the jaw, but previous 
reports suggest it ranges from under 1% with clodronate, 
ibandronate, or 6-monthly zoledronic acid12,13,29 to about 2% 
with more intensive zoledronic acid schedules.30
These trials have shown that  some years of adjuvant 
bisphosphonate treatment can reduce breast cancer 
recurrence rates in bone and improve breast cancer 
survival, but have provided clear evidence of beneﬁ t only 
in women who are postmenopausal (natural or induced) 
at the time bisphosphonates are started. The use of 
bisphosphonates in breast cancer is mainly to reduce 
bone loss and risk of fracture in postmenopausal 
women with ER-positive disease treated with aromatase 
inhibitors. Our results show that such bisphosphonate 
treatment can, in addition, provide oncological beneﬁ t, 
and suggest that adjuvant bis phosphonates should be 
considered in a broader range of postmenopausal women.
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